Personalis, Inc. 8K

Personalis agreed to be acquired by Tempus AI in an approximately $1.5 billion, primarily stock-funded transaction to integrate Personalis’ MRD technology into Tempus’ AI-enabled precision oncology platform, pending shareholder and regulatory approvals.

On July 20, 2026, Personalis, Inc. announced it entered into a definitive agreement to be acquired by Tempus AI, Inc. in an all‑stock transaction valuing Personalis at $16.25 per share, or approximately $1.5 billion in enterprise value net of Tempus’ existing stake, with Tempus acquiring all outstanding Personalis shares it does not already own via a floating exchange ratio of Tempus stock (capped at 0.3356 shares per Personalis share) and an option, at Tempus’ discretion, to pay up to 50% of the consideration in cash financed with cash on hand and credit facilities; the deal, approved by both boards and expected to close in late 2026 or early 2027 subject to shareholder and regulatory approvals, is intended to combine Tempus’ multimodal data and AI precision oncology platform with Personalis’ tumor‑informed minimal residual disease (MRD) technology, expanding Tempus’ presence across the cancer care continuum and positioning the combined company to capitalize on the growing MRD market.

Filing Facts

CIK

1527753

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-308488

Alert Tier

8